Company Focus
Novartis
Latest Novartis News
Pharmaceutical
The Swiss government has met with senior executives from Roche and Novartis to discuss the outlook for the pharmaceutical industry amid escalating US trade measures. 15 August 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to Novartis
Pharmaceutical
The Swiss government has met with senior executives from Roche and Novartis to discuss the outlook for the pharmaceutical industry amid escalating US trade measures. 15 August 2025
Pharmaceutical
A first-of-its-kind study from UK pharm major AstraZeneca and Macmillan Cancer Support into the barriers around access to the latest biomarker testing for cancer in the UK has been published in Future Oncology. 15 August 2025
Pharmaceutical
Eli Lilly has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity. 15 August 2025
Biotechnology
Pilatus Biosciences, a US biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced a clinical trial collaboration with Swiss pharma giant Roche. 14 August 2025
Pharmaceutical
China-based RNA therapeutics developer Ribopeutic has raised close to 100 million yuan ($13.9 million) in pre-A financing, with Tasly Holding Group and Pan-Lin Asset Management leading the round. 14 August 2025
Biotechnology
Maryland, USA-based biotech MacroGenics announced that effective as of August 13, 2025, Eric Risser has been appointed president, chief executive (CEO) and to the board of directors. 14 August 2025
Pharmaceutical
Danish CNS specialist Lundbeck has reported revenue grew 14% at constant exchange rates (CER), plus 14% DKK, to 12,258 million kroner ($1,915 million) in the first six months of 2025. Growth in the USA and Europe was the driver of this strong performance. 14 August 2025
Biotechnology
Sino-American biotech BeOne Medicines has announced financial results from the second quarter of 2025. 13 August 2025
Pharmaceutical
Evotec reported second-quarter 2025 revenues of $188 million, down 6% year-on-year, as strength in its biologics division partly offset weaker demand in discovery and preclinical services. Net loss narrowed to $48 million from $103 million, with earnings per share at minus $0.24. 13 August 2025
Biotechnology
Germany’s Bayer and privately-held Kumquat Biosciences, a US biotech founded by pioneers of the KRAS pathway, have entered into an exclusive global license and collaboration to develop and commercialize the US firm’s KRAS G12D inhibitor. 12 August 2025
Latest In Brief for Novartis
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Ones To Watch News
US specialty pharma business SERB Pharmaceuticals is acquiring Y-mAbs Therapeutics in a $412 million all-cash deal that brings the pediatric cancer drug Danyelza (naxitamab-gqgk) into its rare oncology portfolio. 6 August 2025
18 July 2025
Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze